SNCA and Parkinson disease: Moreover, Mittal and colleagues [39] found that the treatments with β2-adrenergic receptor ligands modulate α-synuclein expression, suggesting that β2-adrenergic receptor agonists reduce the risk of developing PD by countering the α-synuclein-induced inflammatory pathways.